Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies.

Yue Ye Huang, Aaron M Gusdon, Shen Qu

Journal: Lipids in health and disease 2014;12():171

PMID: 24209497

Free Full Text on BioMed Central View on PubMed

Abstract

Along with rising numbers of patients with metabolic syndrome, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased in proportion with the obesity epidemic. While there are no established treatments for NAFLD, current research is targeting new molecular mechanisms that underlie NAFLD and associated metabolic disorders. This review discusses some of these emerging molecular mechanisms and their therapeutic implications for the treatment of NAFLD. The basic research that has identified potential molecular targets for pharmacotherapy will be outlined.

Address: Department of Endocrinology and Metabolism, Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China. [email protected].

DOI: 10.1186/1476-511X-12-171

Link outs

Free resources

Full Text Sources:

Other Literature Sources:

https://scite.ai/reports/24209497

Miscellaneous:

https://assays.cancer.gov/CPTAC-1323

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-FOXO1-1

MeSH Terms: Curcumin, Fatty Acid Synthase, Type I, Fatty Liver, Fibric Acids, Forkhead Box Protein O1, Forkhead Transcription Factors, Gene Expression Regulation, Humans, Lipid Metabolism, Liver, Mitochondria, Non-alcoholic Fatty Liver Disease, PPAR gamma, Peroxisomes, Pregnane X Receptor, Protective Agents, Receptors, Cytoplasmic and Nuclear, Receptors, Steroid, Thiazolidinediones